Please login to the form below

Not currently logged in
Email:
Password:

Exelixis appoints Andrew Peters to newly created position

He joins the biotech as its vice president, strategy

ExelixisCalifornia, US-based biotechnology group Exelixis has appointed Andrew Peters as vice president of strategy.

In this newly created role, Peters will work with the Exelixis leadership team to refine the company’s mid- and long-term strategy, which is focused on advancing the next generation of Exelixis medicines.

Commenting on his appointment, Michael Morrissey, president and chief executive officer of Exelixis, said: “Andrew’s extensive experience as a biotechnology industry analyst makes him a valuable addition to the Exelixis team as we work to identify potential future growth opportunities for the company.

“His familiarity with Exelixis and the biotech landscape should make for a seamless transition into his new role.”

Prior to his new role, Peters served as a director and senior analyst for Deutsche Bank Securities.

He has also held roles UBS Securities, Susquehanna International Group and Morgan Joseph & Co.

11th June 2018

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Innovative Trials

Innovative Trials is a leading global clinical trial patient recruitment company. With over 10 years’ experience, Innovative Trials deploys “boots-on-the-ground”...

Latest intelligence

Tree
Pharma’s vital role in sustainability and corporate social responsibility
Pharma is in the spotlight as tough questions about sustainability commitments continue to arise...
Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study....
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space....